Maller, Ori http://orcid.org/0000-0002-4149-0179
Drain, Allison P.
Barrett, Alexander S.
Borgquist, Signe
Ruffell, Brian http://orcid.org/0000-0002-3846-6872
Zakharevich, Igor
Pham, Thanh T.
Gruosso, Tina
Kuasne, Hellen
Lakins, Johnathon N.
Acerbi, Irene
Barnes, J. Matthew
Nemkov, Travis http://orcid.org/0000-0001-8566-7119
Chauhan, Aastha
Gruenberg, Jessica
Nasir, Aqsa http://orcid.org/0000-0003-3134-2874
Bjarnadottir, Olof
Werb, Zena
Kabos, Peter
Chen, Yunn-Yi
Hwang, E. Shelley
Park, Morag http://orcid.org/0000-0001-5400-606X
Coussens, Lisa M. http://orcid.org/0000-0003-2389-1865
Nelson, Andrew C. http://orcid.org/0000-0002-4741-0010
Hansen, Kirk C.
Weaver, Valerie M. http://orcid.org/0000-0003-4786-6752
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32 CA 108462, TL1 TR001081, T32 HL007171, R01 CA057621, T32 CA 108462, R01 CA057621)
Vetenskapsrådet
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA222508-01, R33 CA183685, R01CA192914, CA174929, R01CA222508-01)
Masonic Cancer Center at the University of Minnesota
Article History
Received: 8 December 2017
Accepted: 30 September 2020
First Online: 30 November 2020
Competing interests
: The authors declare the following competing interests: L.M.C. is a paid consultant for Cell Signaling Technologies, Shasqi Inc., and AbbVie Inc., and received reagent and/or research support from Plexxikon Inc., Pharmacyclics, Inc., Acerta Pharma, LLC, Deciphera Pharmaceuticals, LLC, Genentech, Inc., Roche Glycart AG, Syndax Pharmaceuticals Inc., Innate Pharma and NanoString Technologies, and is a member of the scientific advisory boards of Syndax Pharmaceuticals, Carisma Therapeutics, Zymeworks, Inc., Verseau Therapeutics, Cytomix Therapeutics, Inc. and Kineta Inc. T.N. and K.C.H. are co-founders of Omix Technologies.